In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Role of new biomarkers in prognosis of acute kidney injury in patients with acute myocardial infarction

Session Poster Session 4 - Acute Coronary Syndromes (Other)

Speaker Associate Professor Irina Vishnevskaya

Event : Acute Cardiovascular Care 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Poster Session

Authors : YV Hilova (Kharkiv,UA), IRYNA Vyshnevska (Kharkiv,UA), OV Petyunina (Kharkiv,UA), MP Kopytsya (Kharkiv,UA), JV Rodionova (Kharkiv,UA)

Authors:
YV Hilova1 , IRYNA Vyshnevska1 , OV Petyunina1 , MP Kopytsya1 , JV Rodionova1 , 1Government institution“L.T. Malaya Therapy National institute of the National academy of medical sci - Kharkiv - Ukraine ,

Citation:
European Heart Journal Supplement ( 2018 ) 7 ( Supplement ), S266

Acute kidney injury (AKI) is a common complication of acute myocardial infarction (AMI), but has not been well studied so far. AKI strongly associates with long-term mortality, especially in those patients, who underwent primary percutaneous coronary intervention (PCI). In order to diagnose this condition in time the search for new biomarkers is going. One of them is the soluble ST2 (sST2).
Purpose: to estimate the role of various markers in the AKI formation in patients with AMI
Methods: 103 patients were screened with ST segment elevation myocardial infarction (STEMI) (75 male and 28 female), mean age was 61,85 ± 12,23 years. In anamnesis patients had: 15% - previous myocardial infarction, 26% - stable angina, 79% - hypertension, 26% - diabetes mellitus. All patients had to undergo baseline investigations, including the level of serum creatinine; the glomerular filtration rate (GFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Accordingly to the result, all patients have been divided into two groups with the GFR level less and greater than 60 mL/min/1.73 m2. In addition, during the first day of hospitalization the sST2 and N-terminal pro-brain natriuretic peptide (NT-pro BNP) were determined.
Results: During the statistical analysis the mean value of sST2 in the first group was 84.06 pg/ml, in the second – 52.84; the mean value for NT- pro BNP was 846.69 pg/ml and 447.28 pg/ml, respectively. GFR has been calculated, the average was 45 ml/min/1.73m2 in the first group and 73 ml/min/1.73m2 in the second. By comparing selected groups significant difference in GFR was found (? < 0.0001). The analyses of biomarkers interconnection (NT pro-BNP, sST2) showed significant difference of estimated parameters in both groups as well (? ≤ 0.03; ? ≤ 0.02, respectively). Also, correlation of medium strength between biomarkers (sST2, NT pro-BNP) and GFR (r=0.4, ? ≤ 0.0001; r=0.4, p≤0.001) was found.
Conclusions: The biomarker sST2 can be used for risk stratification of AKI development in patients with STEMI; it’s as sensitive as the known marker NT- pro BNP. For high prognostic possibility we can use combination of biomarkers.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are